Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rysk (rysk.bio) is a biotechnology and biosecurity company focused on safeguarding the synthetic biology ecosystem through advanced DNA synthesis screening. The company develops technology to screen DNA orders for potential biological threats, such as pathogens and toxins, ensuring that synthetic genetic material is used for legitimate research and development. By providing automated sequence and customer screening solutions, Rysk helps DNA synthesis providers comply with international biosecurity standards and government regulations. Its platform acts as a critical chokepoint to prevent the accidental or intentional creation of dangerous biological agents while supporting the continued innovation of the life sciences industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rysk.